Keli Song

发表

Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.

J. Kutok, R. Khosravi‐Far, S. Ghaffari, 2009, Cancer research.

Transduction of tumor necrosis factor-related apoptosis-inducing ligand into hematopoietic cells leads to inhibition of syngeneic tumor growth in vivo.

R. Khosravi‐Far, Keli Song, Robin L. Anderson, 2006, Cancer research.

Fas-associated Protein with Death Domain (FADD)-independent Recruitment of c-FLIPL to Death Receptor 5*

B. Kay, R. Khosravi‐Far, Keli Song, 2004, Journal of Biological Chemistry.

Quest for molecular markers in adult soft tissue tumors

R. Khosravi‐Far, Keli Song, 2006, Cancer Biology & Therapy.

Knocking down Siglec-15 in osteosarcoma cells inhibits proliferation while promoting apoptosis and pyroptosis by targeting the Siglec-15/STAT3/Bcl-2 pathway.

Keli Song, B. Yue, Y. Qu, 2022, Advances in medical sciences.

Priming of the vascular endothelial growth factor signaling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase.

R. Khosravi‐Far, J. Lawler, Keli Song, 2011, Blood.

Siglec-15-induced autophagy promotes invasion and metastasis of human osteosarcoma cells by activating the epithelial–mesenchymal transition and Beclin-1/ATG14 pathway

Keli Song, Lingling Sun, B. Yue, 2022, Cell & bioscience.

Analysis of TNF-related apoptosis-inducing ligand in vivo through bone marrow transduction and transplantation.

Rajan Mariappan, R. Khosravi‐Far, Keli Song, 2008, Methods in enzymology.

In vivo to Inhibition of Syngeneic Tumor Growth Apoptosis-Inducing Ligand into Hematopoietic Cells Leads Related − Transduction of Tumor Necrosis Factor

R. Khosravi‐Far, Keli Song, Robin L. Anderson, 2006 .

A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR.

R. Khosravi‐Far, J. Lawler, B. Ren, 2009, Cancer research.

Apoptotic pathways in tumor progression and therapy.

R. Khosravi‐Far, Zainab Jagani, Keli Song, 2008, Advances in experimental medicine and biology.

A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models

Steven S. Langston, Xingyue He, E. Lightcap, 2021, Science Translational Medicine.

Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer.

Xingyue He, M. Mizutani, T. Soucy, 2021, Journal of medicinal chemistry.

The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation

Kristina Xega, A. Berger, Keli Song, 2022, Blood.

Abstract B154: Application of preclinical combination pharmacokinetic(PK)/efficacy(E) modeling to investigate and translate the preclinical scheduling effect for MLN1117 and Taxotere combination

Dong Zhang, K. Kannan, C. Zopf, 2015 .

killerFLIP: a novel lytic peptide specifically inducing cancer cell death

R. Khosravi‐Far, Keli Song, W. Malorni, 2013, Cell Death and Disease.

A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR.

R. Khosravi‐Far, J. Lawler, B. Ren, 2009, Cancer Research.

The Sumoylation Inhibitor TAK-981 in Combination with the CD19-Targeting Antibody Tafasitamab Shows Enhanced Anti-Tumor Activity in Preclinical B-Cell Lymphoma Models

A. Berger, Keli Song, A. Nakamura, 2021, Blood.